← Back to Search

Genetic Testing Education for Cancer Survivors (CATALYST Trial)

Phase < 1

Recruiting

Led By Anita Y Kinney, PhD, RN

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial, or prostate cancer

Have not previously undergone GT for hereditary cancer predisposition

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1-month, 6-months

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve genetic education and testing for cancer survivors who may have a hereditary risk of cancer. The study will focus on developing and testing a digital intervention called CATALYST, which will

Who is the study for?

This trial is for cancer survivors with specific cancers such as breast, ovarian, prostate, colorectal and pancreatic. Participants should be interested in learning about their genetic risk of cancer through testing and education using smart technology.

What is being tested?

The study tests a digital tool called CATALYST (a relational assistant) against enhanced usual care to see if it improves genetic education and testing uptake among cancer survivors. Participants will be randomly placed into one of these two groups.

What are the potential side effects?

Since this is an observational study focusing on educational tools rather than medical treatments, traditional physical side effects are not applicable. However, participants may experience emotional or psychological impacts from learning about their genetic risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a specific type of cancer.

Select...

I have never had gene therapy for inherited cancer risk.

Select...

I was diagnosed with specific cancers at a certain age or have a high-risk prostate cancer.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1-month, 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1-month, 6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-month, 6-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants with Genetic Testing Uptake

Secondary study objectives

Acceptance and Usability of the Relational Agent

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Relational Agent (RA)Experimental Treatment1 Intervention

RA participants will be provided with access to Alex, the RA. After completing the RA, RA participants can proceed directly to GT.

Group II: Enhanced Usual Care (EUC)Active Control1 Intervention

EUC participants will be sent a clinical letter informing them of their increased risk of hereditary cancer, availability of GC and GT services, and contact information to schedule an appointment with a genetic counselor at the LIFE Center.

0 / 4Eligibility criteria met